All Journals > Clinical Infectious Diseases > 1 December 2006 > Rifapentine for Tuberculosis Treatment

Article Tools

Search for Related Articles

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

1 December 2006

Volume 43, Number 11
Clinical Infectious Diseases 2006;43:1468–1475
This article is in the public domain, and no copyright is claimed.
1058-4838/2006/4311-0017
DOI: 10.1086/508278
REVIEWS OF ANTI‐INFECTIVE AGENTS INVITED ARTICLE

Rifapentine for the Treatment of Pulmonary Tuberculosis

Sonal S. Munsiff,1,2

Chrispin Kambili,1 and

Shama Desai Ahuja1

1New York City Department of Health and Mental Hygiene, New York; and 2Centers for Disease Control and Prevention, Atlanta, Georgia

Rifapentine is a recently approved antituberculosis drug that has not yet been widely used in clinical settings. Clinical data support intermittent use of rifapentine with isoniazid during the continuation phase of tuberculosis treatment. Patients with culture‐positive, noncavitary, pulmonary tuberculosis whose sputum smear is negative for acid‐fast bacilli at the end of the 2‐month intensive treatment phase are eligible for rifapentine therapy. Rifapentine should not be used in human immunodeficiency virus–infected patients, given their increased risk of developing rifampin resistance with currently recommended dosages. Rifapentine is not currently recommended for children aged <12 years, pregnant or lactating women, or individuals with culture‐negative or extrapulmonary tuberculosis. Rifapentine (600 mg) is administered once weekly with isoniazid (900 mg) during the continuation phase of treatment. This combination should only be given under direct observation. As with rifampin, drug‐drug interactions are common, and regular patient monitoring is required. Ease of administration makes this regimen attractive both for tuberculosis‐control programs and for patients.

Received 24 January 2006; accepted 8 June 2006; electronically published 24 October 2006.

Reprints or correspondence: Dr. Sonal S. Munsiff, Bureau of Tuberculosis Control, New York City Dept. of Health and Mental Hygiene, 225 Broadway, 22nd Fl., CN72B, New York, NY 10007 ().

Louis D. Saravolatz, Section Editor

Cited by

Andrea T Cruz, Jeffrey R Starke. (2009) Treatment of tuberculosis in children. Expert Review of Anti-infective Therapy 6:6, 939-957
Online publication date: 1-Jan-2009.
CrossRef
Back to Top
Close Popup